A perspective on quantitative structure–activity relationships and carbonic anhydrase inhibitors

Bibliography

• SUPURAN CT, SCOZZAFAVA A, CASINI A: Carbonic anhydrase inhibitors. Med. Res. Rev. (2003) 23:146-189.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, VULLO D, MANOLE G, CASINI A, SCOZZAFAVA A: Designing of novel carbonic anhydrase inhibitors and activators. Curr. Med. Chem. – Cardiovasc. Hematol. Agents (2004) 2:49-68.
   PubMedGoogle Scholar
• SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. Ther. Patents (2002) 12:217-242.
   Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors. Curr. Med. Chem.- Imm., Endoc. Metab. Agents (2001) 1:61-97.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents (2000) 10:575-600.
   Web of Science ®Google Scholar
• COX EH, MCLENDON GL, MOREL FM et al.: The active site structure of Thalassiosira weissflogii carbonic anhydrase 1. Biochemistry (2000) 39:12128-12130.
   PubMed Web of Science ®Google Scholar
• LANE TW, MOREL FM: A biological function for cadmium in marine diatoms. Proc. Natl. Acad. Sci. USA (2000) 97:4627-4631.
   PubMed Web of Science ®Google Scholar
• SO AK, ESPIE GS, WILLIAMS EB et al.: A novel evolutionary lineage of carbonic anhydrase (epsilon class) is a component of the carboxysome shell. J. Bacteriol. (2004) 186:623-630.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A, CONWAY J: Carbonic anhydrase – Its inhibitors and activators. CRC Press Boca Raton, FL, USA (2004).
   Google Scholar
• PASTOREKOVA S, PARKKILA S, PASTOREK J, SUPURAN CT: Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enz. Inhib. Med. Chem. (2004) 19:199-229.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT: Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Patents (2003) 13:1545-1550.
   Web of Science ®Google Scholar
• MITSUHASHI S, MIZUSHIMA T, YAMASHITA E et al.: X-ray structure of beta-carbonic anhydrase from the red alga Porphyridium purpureum, reveals a novel catalytic site for CO2 hydration. J. Biol. Chem. (2000) 275:5521-5526.
   PubMed Web of Science ®Google Scholar
• STROP P, SMITH KS, IVERSON TM, FERRY JG, REES DC: Crystal structure of the ‘cab’-type beta class carbonic anhydrase from the archaeon Methanobacterium thermoautotrophicum. J. Biol. Chem. (2001) 276:10299-10305.
   PubMed Web of Science ®Google Scholar
• KIMBER MS, PAI EF: The active site architecture of Pisum sativum β-carbonic anhydrase is a mirror image of that of α-carbonic anhydrases. EMBO J. (2000) 19:1407-1418.
   PubMed Web of Science ®Google Scholar
• CRONK JD, ENDRIZZI JA, CRONK MR, O’NEILL JW, ZHANG KY: Crystal structure of E. coli β-carbonic anhydrase, an enzyme with an unusual pH-dependent activity. Protein Sci. (2001) 10:911-922.
   PubMed Web of Science ®Google Scholar
• LINDSKOG S, SILVERMAN DN: In: The Carbonic Anhydrases – New Horizons. WR Chegwidden, YH Edwards, ND Carter (Eds), Birkhäuser Verlag Basel (2000):175-196.
   Google Scholar
• ABBATE F, CASINI A, OWA T, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. (2004) 14:217-223.
   PubMed Web of Science ®Google Scholar
• CASINI A, ANTEL J, ABBATE F et al.: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. (2003) 13:841-845.
   PubMed Web of Science ®Google Scholar
• ABBATE F, COETZEE A, CASINI A et al.: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg. Med. Chem. Lett. (2004) 14:337-341.
   PubMed Web of Science ®Google Scholar
• WEBER A, CASINI A, HEINE A et al.: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47:550-557.
   PubMed Web of Science ®Google Scholar
• ABBATE F, SUPURAN CT, SCOZZAFAVA A et al.: Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J. Med. Chem. (2002) 45:3583-3587.
   PubMed Web of Science ®Google Scholar
• CASINI A, ABBATE F, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamide-two heads are better than one? Bioorg. Med. Chem. Lett. (2003) 13:2759-2763.
   PubMed Web of Science ®Google Scholar
• ABBATE F, CASINI A, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. J. Enz. Inhib. Med. Chem. (2003) 18:303-308.
   PubMed Web of Science ®Google Scholar
• MANN T, KEILIN D: Carbonic anhydrase: chemistry, physiology and inhibition. Physiol. Rev. (1967) 47:595-781.
   PubMed Web of Science ®Google Scholar
• MAREN TH: Carbonic anhydrase: chemistry, physiology and inhibition. Physiol. Rev. (1967) 47:595-781.
   PubMed Web of Science ®Google Scholar
• MAREN TH: The development of topical carbonic anhydrase inhibitors. J. Glaucoma (1995) 4:49-62.
   PubMedGoogle Scholar
• SUPURAN CT: Indisulam: an anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs (2003) 12:283-287.
   PubMed Web of Science ®Google Scholar
• PASTOREKOVA S, PASTOREK J: Cancer-related carbonic anhydrase isozymes and their inhibition. In: Carbonic anhydrase – Its inhibitors and activators. CT Supuran, A Scozzafava, J Conway (Eds), CRC Press Boca Raton, FL, USA (2004):253-280.
   Google Scholar
• VULLO D, FRANCHI M, GALLORI E et al.: Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. (2003) 13:1005-1009.
   PubMed Web of Science ®Google Scholar
• LIAO SY, IVANOV S, IVANOVA A et al.: Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CA XII) in glaucoma. J. Med. Genet. (2003) 40:257-261.
   PubMed Web of Science ®Google Scholar
• POTTER C, HARRIS AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle (2004) 3:164-167.
   PubMed Web of Science ®Google Scholar
• SVASTOVA E, ZILKA N, ZAT’OVICOVA M et al.: Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. Exp. Cell Res. (2003) 290:332-345.
   PubMed Web of Science ®Google Scholar
• GUT MO, PARKKILA S, VERNEROVA Z et al.: Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology (2002) 123:1889-1903.
   PubMed Web of Science ®Google Scholar
• ZAT’OVICOVA M, TARABKOVA K, SVASTOVA E et al.: Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J. Immunol. Methods (2003) 282:117-134.
   PubMed Web of Science ®Google Scholar
• KALUZ S, KALUZOVA M, CHRASTINA A et al.: Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 α stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res. (2002) 62:4469-4477.
   PubMed Web of Science ®Google Scholar
• HOSKIN PJ, SIBTAIN A, DALEY FM, WILSON GD: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer (2003) 89:1290-1297.
   PubMed Web of Science ®Google Scholar
• HEDLEY D, PINTILIE M, WOO J et al.: Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin. Cancer Res. (2003) 9:5666-5674.
   PubMed Web of Science ®Google Scholar
• BARTOSOVA M, PARKKILA S, POHLODEK K et al.: Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J. Pathol. (2002) 197:314-321.
   PubMed Web of Science ®Google Scholar
• TOMES L, EMBERLEY E, NIU Y et al.: Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res. Treat. (2003) 81:61-69.
   PubMed Web of Science ®Google Scholar
• SVASTOVA E, HULIKOVA A, RAFAJOVA M et al.: Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. (2004) 577:439-445.
   PubMed Web of Science ®Google Scholar
• GUPTA SP: Quantitative structure–activity relationships of carbonic anhydrase inhibitors. Prog. Drug Res. (2003) 60:172-204.
   Google Scholar
• CLARE BW: Frontier orbital energies in quantitative structure–activity relationships: a comparison of quantum chemical methods. Theor. Chim. Acta (1994) 87:415-430.
   Google Scholar
• SHULGIN A, SHULGIN A: PIHKAL: A Chemical Love Story. Transform Press: Box 13675, Berkeley, California, US (1991).
   Google Scholar
• OVERTON E: Studies uber die Narkose zugleich ein betrag zur Alllgemeinen Pharmacologie. Verlag von Gustav Fischer Jena (1901).
   Google Scholar
• MEYER KH: Theorie der alkoholnarkose. Arch Exp. Patrol. Pharmakol. (1899) 42:109-118.
   Google Scholar
• CROS AFA: Thesis. University of Strasbourg, Strasbourg, France (1863).
   Google Scholar
• TANG P, YAN B, YAN X: Different distribution of fluorinated anesthetics and nonanesthetics in model membrane: a 19F NMR study. Biophys. J. (1997) 72:1676-1682.
   PubMed Web of Science ®Google Scholar
• TAHERI S, LASTER MJ, LIU J et al.: Anaesthesia ny n-alkanes not consistent with the Meyer-Overton Hypothesis: determination of the solubility of alkanes in saline and various lipids. Anesth. Analg. (2002) 77:7-11.
   Google Scholar
• GOLBREAKH A, TROPSHA A: Beware of q2! J. Mol. Graphics Model. (2002) 44:269-276.
   Google Scholar
• MAREN TH: Relatons between structure and biological activity of sulfonamides. Ann. Rev. Pharmacol. Toxicol. (1976) 16:309-327.
   PubMed Web of Science ®Google Scholar
• KAKEYA N, AOKI M, KAMADA A, YATA N: Biological activities of drugs. VI. Structure–activity relation of sulfonamide carbonic anhydrase inhibitors. Chem. Pharm. Bull. (1969) 17:1010-1018.
   PubMed Web of Science ®Google Scholar
• KAKEYA N, YATA N, KAMADA A, AOKI M: Biological activities of drugs VII. Structure–activity relation of sulfonamide carbonic anhydrase inhibitors. Chem. Pharm. Bull. (1969) 17:2000-2007.
   PubMed Web of Science ®Google Scholar
• KAKEYA N, YATA N, KAMADA A, AOKI M: Biological activities of drugs. VIII. Structure–activity relation of sulfonamide carbonic anhydrase inhibitors. Chem. Pharm. Bull. (1969) 17.
   Google Scholar
• KAKEYA N, YATA N, KAMADA A, AOKI M: Biological activities of drugs. IX. Structure–activity relation of sulfonamide carbonic anhydrase inhibitors. 4. Chem. Pharm. Bull. (1970) 18:191-194.
   Google Scholar
• DEBENEDETTI PG, MENZIANI MC: A quantum chemical QSAR study of carbonic anhydrase inhibition by sulfonamides, sulfonamide carbonic anhydrase inhibitors: quantum chemical QSAR. QSAR (1985) 4:23-28.
   Google Scholar
• CAROTTI A, RAGUSEO C, CAMPAGNA F, LANGRIDGE R, KLEIN TE: Inhibition of carbonic anhydrase by substituted benzenesulfonamides. A reinvestigation by QSAR and molecular graphics analysis. QSAR (1985) 8:1-10.
   Google Scholar
• HANSCH C, MCLARIN J, KLEIN T, LANGRIDGE R: A quantitative structure–activity relationship and molecular graphics study of carbonic anhydrase inhibitors. Mol. Pharmacol. (1985) 27:493-498.
   PubMed Web of Science ®Google Scholar
• MAREN TH, CONROY CW: A new class of carbonic anhydrase inhibitor. J. Biol. Chem. (1993) 268:26233-26239.
   PubMed Web of Science ®Google Scholar
• KUMAR K, BINDAL MC, SINGH P, GUPTA SP: Effect of molecular size on carbonic anhydrase inhibition by sulfonamides. Int. J. Quantum Chem. (1981) 20:123-129.
   Web of Science ®Google Scholar
• KISHIDA K, MANABE R: The role of the hydrophobicity of the substituted groups of dichlorphenamide in the development of carbonic anhydrase inhibition. Med. J. Osaka Univ. (1980) 30:95-100.
   PubMedGoogle Scholar
• CLARE BW: QSAR of benzene derivatives: comparison of classical descriptors, quantum theoretic parameters and flip regression, exemplified by phenylalkylamine hallucinogens. J. Comput.-Aided Mol. Des. (2002) 16:611-633.
   PubMed Web of Science ®Google Scholar
• CLARE BW, SUPURAN CT: A physically interpretable quantum-theoretic QSAR for some carbonic anhydrase inhibitors with diverse aromatic rings, obtained by a new QSAR procedure. Bioorg. Med. Chem. (2005) 13:2197-2211.
   PubMed Web of Science ®Google Scholar
• KISHIDA K: 1,3,4-Thiadiazole-5-sulfonamides as carbonic anhydrase inhibitors: relationship between their electronic and hydrophobic structures and their inhibitory activity. Chem. Pharm. Bull. (1978) 26:1049-1053.
   PubMed Web of Science ®Google Scholar
• DEBENEDETTI PG, MENZIANI M, COCCHI MC, FRASSINETI G: A quantum chemical QSAR analysis of carbonic anhydrase inhibition by heterocyclic sulfonamides, sulfonamide carbonic anhydrase inhibitors: quantum chemical QSAR. QSAR (1987) 6:51-53.
   Google Scholar
• CLARE BW, SUPURAN CT: Carbonic anhydrase inhibitors. Part 41. Quantitative structure–activity correlations involving kinetic rate constants of 20 sulfonamide inhibitors from a non-congeneric series. Eur. J. Med. Chem. (1997) 32:311-319.
   Web of Science ®Google Scholar
• BREIMAN L, FRIEDMAN JH: Estimating optimal transformations for multiple regression and correlation. J. Am. Statist. Assoc. (1985) 80:580-619.
   Web of Science ®Google Scholar
• SCOZZAFAVA A, MENABUONI L, MINCIONE F et al.: Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J. Med. Chem. (2000) 43:4542.
   PubMed Web of Science ®Google Scholar
• MATTIONI BE, JURS PC: Development of quantitative structure–activity relationship and classification models for a set of carbonic anhydrase inhibitors. J. Chem. Inf. Comput. Sci. (2002) 42:94-102.
   PubMedGoogle Scholar
• CLARE BW: The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens. J. Med. Chem. (1998) 41:3845-3856.
   PubMed Web of Science ®Google Scholar
• CLARE BW: A novel quantum theoretic QSAR for hallucinogenic tryptamines: a major factor is the orientation of p orbital nodes. Theochem (2004) 712:143-148.
   Web of Science ®Google Scholar
• CLARE BW: the frontier orbital phase angles: a theoretical interpretation. Theochem (2000) 507:157-164.
   Web of Science ®Google Scholar
• CLARE BW: The frontier orbital phase angles: a theoretical interpretation. Theochem (2001) 535:301. [Erratum to document cited in CA133:217267].
   Web of Science ®Google Scholar
• SCOZZAFAVA A, BRIGANTI F, ILIES MA, SUPURAN CT: Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J. Med. Chem. (2000) 43:292-300.
   PubMed Web of Science ®Google Scholar
• GUPTA SP, KUMARAN S: A quantitative structure–activity relationship study on some aromatic/heterocyclic sulfonamides and their charged derivatives acting as carbonic anhydrase inhibitors. J. Enz. Inhib. Med. Chem. (2005) 20:251-259.
   PubMed Web of Science ®Google Scholar
• MAREN TH, CLARE BW, SUPURAN CT: Structure–activity studies of sulfonamide carbonic anhydrase inhibitors. Roum. Chem. Quart. Rev. (1994) 2:259-282.
   Google Scholar